|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, July 22, 2017 ) Obsessive-compulsive disorder (OCD) is characterized by unreasonable thoughts and fears (obsessions) that lead to do repetitive behaviors (compulsions) . Symptoms include having repeated thoughts or images about many different things such as fear of germs dirt or intruders acts of violence hurting loved ones doing the same rituals over and over such as washing hands locking and unlocking doors counting keeping unneeded items or repeating the same steps again and again. Risk factor includes family history. Treatment includes antidepressants and psychiatric medications.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Obsessive-Compulsive Disorder-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Obsessive-Compulsive Disorder (Central Nervous System) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.
The Obsessive-Compulsive Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Obsessive-Compulsive Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Pre-Registration Preclinical and Discovery stages are 1 6 and 1 respectively.
Obsessive-Compulsive Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/obsessive-compulsive-disorder-pipeline-review-h2-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Obsessive-Compulsive Disorder (Central Nervous System) .
- The pipeline guide reviews pipeline therapeutics for Obsessive-Compulsive Disorder (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Obsessive-Compulsive Disorder (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Obsessive-Compulsive Disorder (Central Nervous System) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Obsessive-Compulsive Disorder (Central Nervous System)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001881435/sample
Reasons to buy
- Procure strategically important competitor information analysis and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Obsessive-Compulsive Disorder (Central Nervous System) .
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Obsessive-Compulsive Disorder (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
AbbVie Inc
Addex Therapeutics Ltd
Amorsa Therapeutics Inc
Omeros Corp
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001881435/discount
List of Tables
Number of Products under Development for Obsessive-Compulsive Disorder H2 2017
Number of Products under Development by Companies H2 2017
Products under Development by Companies H2 2017
Number of Products by Stage and Target H2 2017
Number of Products by Stage and Mechanism of Action H2 2017
Number of Products by Stage and Route of Administration H2 2017
Number of Products by Stage and Molecule Type H2 2017
Obsessive-Compulsive Disorder-Pipeline by AbbVie Inc H2 2017
Obsessive-Compulsive Disorder-Pipeline by Addex Therapeutics Ltd H2 2017
Obsessive-Compulsive Disorder-Pipeline by Amorsa Therapeutics Inc H2 2017
Obsessive-Compulsive Disorder-Pipeline by Omeros Corp H2 2017
Obsessive-Compulsive Disorder-Dormant Projects H2 2017
Obsessive-Compulsive Disorder-Discontinued Products H2 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001881435/buy/2000
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
